Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Peginterferon Treatment in HBV Liver Fibrosis
NCT03920605Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2a and peginterferon alfa-2b in Chronic Hepatitis B (CHB) and Liver Fibrosis (LF) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Change of level of liver fibrosis after anti-virus treatment at 144 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2apeginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT03920605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920605.